Dissecting visceral fibromuscular dysplasia reveals a new vascular phenotype of the disease: a report from the ARCADIA-POL study.

OBJECTIVE Visceral artery fibromuscular dysplasia (VA FMD) manifestations range from asymptomatic to life-threatening. The aim of the study is to evaluate the prevalence and clinical characteristics of VA FMD. METHODS A total of 232 FMD patients enrolled into ongoing ARCADIA-POL study were included in this analysis. All patients underwent detailed clinical evaluation including ambulatory blood pressure monitoring, biobanking, duplex Doppler of carotid and abdominal arteries and whole body angio-computed tomography. Three control groups (patients with renal FMD without visceral involvement, healthy normotensive patients and resistant hypertensive patients) matched for age and sex were included. RESULTS VA FMD was present in 32 patients (13.8%). Among these patients (women: 84.4%), FMD lesions were more frequent in celiac trunk (83.1%), 62.5% of patients showed at least one visceral aneurysm, and five patients presented with severe complications related to VA FMD. No demographic differences were found between patients with VA FMD and individuals from the three control groups, with the exception of lower weight (P < 0.001) and BMI (P < 0.001) in VA FMD patients. Patients with FMD (with or without visceral artery involvement) showed significantly smaller visceral arterial diameters compared with controls without FMD. CONCLUSION Patients with FMD showed smaller visceral arterial diameters when compared with patients without FMD. This may reflect a new phenotype of FMD, as a generalized arteriopathy, what needs further investigation. Lower BMI in patients with VA FMD might be explained by chronic mesenteric ischemia resulting from FMD lesions. FMD visceral involvement and visceral arterial aneurysms in patients with renal FMD are far to be rare. This strengthens the need for a systematic evaluation of all vascular beds, including visceral arteries, regardless of initial FMD involvement.

[1]  A. Maas,et al.  Arterial Tortuosity: Novel Implications for an Old Phenotype , 2019, Hypertension.

[2]  M. Litwin,et al.  Association of intrarenal blood flow with renal function and target organ damage in hypertensive patients with fibromuscular dysplasia: the ARCADIA-POL study. , 2019, Polish archives of internal medicine.

[3]  Aditya M. Sharma,et al.  First International Consensus on the diagnosis and management of fibromuscular dysplasia , 2019, Vascular medicine.

[4]  S. Laurent,et al.  Deep Vascular Phenotyping in Patients With Renal Multifocal Fibromuscular Dysplasia , 2019, Hypertension.

[5]  P. Astarci,et al.  Visceral Fibromuscular Dysplasia: From asymptomatic disorder to emergency , 2018, European journal of clinical investigation.

[6]  A. Januszewicz,et al.  Echocardiographic assessment of left ventricular morphology and function in patients with fibromuscular dysplasia: the ARCADIA-POL study , 2018, Journal of hypertension.

[7]  P. Gosse,et al.  High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia) , 2017, Hypertension.

[8]  R. Renapurkar,et al.  Screening CT Angiography of the Aorta, Visceral Branch Vessels, and Pelvic Arteries in Fibromuscular Dysplasia. , 2017, JACC. Cardiovascular imaging.

[9]  B. Kaufman,et al.  Spontaneous hepatic artery dissection—a rare presentation of fibromuscular dysplasia , 2016, Oxford medical case reports.

[10]  Sergio Silveira Leal Meirelles Visceral artery aneurysms. , 2016, Revista do Colegio Brasileiro de Cirurgioes.

[11]  Aditya M. Sharma,et al.  Dissection and Aneurysm in Patients With Fibromuscular Dysplasia: Findings From the U.S. Registry for FMD. , 2016, Journal of the American College of Cardiology.

[12]  Aditya M. Sharma,et al.  Smoking and Adverse Outcomes in Fibromuscular Dysplasia: U.S. Registry Report. , 2016, Journal of the American College of Cardiology.

[13]  E. Kline-Rogers,et al.  Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US Registry , 2016, Pediatric Nephrology.

[14]  W. Drygas,et al.  Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. , 2015, Kardiologia polska.

[15]  K. Kreitner,et al.  Visceral artery aneurysms: Incidence, management, and outcome analysis in a tertiary care center over one decade , 2015, European Radiology.

[16]  X. Jeunemaître,et al.  Association Between 2 Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics , 2012, Circulation.

[17]  K. Eagle,et al.  The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients , 2012, Circulation.

[18]  S. Berceli Hepatic and splenic artery aneurysms. , 2005, Seminars in vascular surgery.

[19]  W. Stone,et al.  Hepatic artery aneurysm: factors that predict complications. , 2003, Journal of vascular surgery.

[20]  P. Kurjata,et al.  [Multicenter national Polish population health status tests--WOBASZ project. Establishment of methods and logistics]. , 2005, Kardiologia polska.

[21]  M. Stowasser,et al.  Increased severity of multifocal renal arterial fibromuscular dysplasia in smokers , 1999, Journal of Human Hypertension.